Healthcare Industry News: metabolic disease
News Release - April 30, 2007
NicOx recruits Sanjiv Sharma as Vice President Commercial Affairs in the United StatesSOPHIA ANTIPOLIS, FRANCE--(Healthcare Sales & Marketing Network)--Apr 30, 2007 -- NicOx S.A. (Eurolist: COX) today announced that it has recruited Sanjiv Sharma as Vice President of Commercial Affairs. Mr. Sharma will be responsible for implementing a global commercial strategy for NicOx' portfolio and defining the strategy for establishing sales and marketing operations in preparation for the launch of naproxcinod, the first compound in the CINOD class and the Company's lead product for the treatment of the signs and symptoms of osteoarthritis.
Mr. Sharma will be based in the United States and he will head NicOx' planned US office in the central New Jersey area, where a NicOx team is expected to be based, including Joan Sutphen, who has been recently named as Director of US Clinical Operations.
Damian Marron, Vice President of Corporate Development at NicOx, declared: "We are delighted to welcome Sanjiv to our executive management team. He brings extensive pharmaceutical industry experience to NicOx, including a strong background in new product introductions and marketing and sales management. His knowledge of the cardiovascular and musculoskeletal areas will be invaluable during the launch preparations for naproxcinod and he will undoubtedly play a key role as NicOx implements its strategy to become an integrated company with commercial operations in the US and EU."
Mr. Sharma will be a member of the NicOx Executive Committee and will report to Damian Marron, Vice President of Corporate Development. Previously, Mr. Sharma led the Strategic Marketing and Business Analysis function at Biovail Pharmaceutical Inc. in the U.S., where he was responsible for new product commercialization and strategic life cycle management across five therapeutic areas, with a special focus on the Ultram® ER franchise for the treatment of chronic pain in adults and the Wellbutrin® XL franchise for the treatment of depression (see NOTE). Prior to that he worked for 15 years at Sanofi-Aventis and its predecessor companies in a variety of positions with increasing responsibility, culminating in his nomination as Director, New Products Commercialization; Metabolism & Cardiovascular; Global Marketing. He has played a significant role in the successful launch, commercialization or life cycle management of numerous products in the US, Canada and globally, such as Actonel® for the treatment of osteoporosis and Cardizem®, Lovenox® and Altace® for treating cardiovascular diseases (see NOTE). Mr. Sharma obtained his MBA in 1997 from the Richard Ivey School of Business at the University of Ontario and was designated as an Ivey Scholar for Scholastic Excellence.
NOTE: Ultram® ER is a registered trademark of Johnson & Johnson; Wellbutrin® XL a registered trademark of The GlaxoSmithKline Group of Companies; Actonel® a registered trademark of Proctor & Gamble Pharmaceuticals Inc.; Cardizem® a registered trademark of Biovail Corporation; Lovenox® a registered trademark of Sanofi-Aventis and Altace® a registered trademark of King Pharmaceuticals.
NicOx (Bloomberg: COX: FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development of nitric oxide-donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of pain and inflammation and cardio-metabolic disease. Resources are focused on two lead compounds, naproxcinod (formerly HCT 3012), in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and NCX 4016, in phase 2 for Type 2 diabetes.
NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer Inc. and Merck and Co., Inc.
NicOx S.A. is headquartered in Sophia-Antipolis, France, and is a public company listed on the Eurolist of EuronextTM Paris (segment: Next Economy).
The elements included in this communication may contain forward-looking statements subject to certain risks and uncertainties. Actual results of the company may differ materially from those indicated in the forward-looking statements because of different risks factors described in the company's document de reference.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.